Open AccessFirst insulinization with basal insulin in patients with Type 2 diabetes in a real‐world setting in Asia
Author(s) -
TSAI ShihTzer,
PATHAN Faruque,
JI Lig,
YEUNG Vincent Tok Fai,
CHADHA Manoj,
SUASTIKA Ketut,
SON Hyun Shik,
TAN Kevin Eng Kiat,
BENJASURATWONG Yupin,
NGUYEN Thy Khue,
IQBAL Farrukh
Publication year - 2011
Publication title -
journal of diabetes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.949
H-Index - 43
eISSN - 1753-0407
pISSN - 1753-0393
DOI - 10.1111/j.1753-0407.2011.00137.x
Subject(s) - medicine , insulin , diabetes mellitus , insulin detemir , hypoglycemia , basal (medicine) , insulin glargine , nph insulin , endocrinology , type 2 diabetes mellitus , type 2 diabetes
Background: The First Basal Insulin Evaluation (FINE) Asia study is a multinational, prospective, observational study of insulin‐naïve Type 2 diabetes mellitus (T2DM) patients in Asia, uncontrolled (A1c ≥ 8%) on oral hypoglycemic agents, designed to evaluate the impact of basal insulin initiation. Methods: Basal insulin was initiated with or without concomitant oral therapy and doses were adjusted individually. All treatment choices, including the decision to initiate insulin, were at the physician’s discretion to reflect real‐life practice. Results: Patients ( n = 2679) from 11 Asian countries were enrolled (mean [±SD] duration of diabetes 9.3 ± 6.5 years; weight 68.1 ± 12.7 kg; A1c 9.8 ± 1.6%). After 6 months of basal insulin (NPH insulin, insulin glargine, or insulin detemir), A1c decreased to 7.7 ± 1.4%; 33.7% patients reached A1c <7%. Fasting blood glucose (FBG) decreased from 11.7 ± 3.6 to 7.2 ± 2.5 mmol/L and 36.8% of patients reached FBG <6.1 mmol/L. The mean daily insulin dose prescribed increased marginally from 0.18 to 0.23 U/kg per day at baseline to 0.22–0.24 U/kg per day at Month 6. Mean changes in body weight and reported rates of hypoglycemia were low over the duration of the study. Conclusions: Initiation of insulin therapy is still being delayed by approximately 9 years, resulting in many Asian patients developing severe hyperglycemia. Initiating insulin treatment with basal insulin was effective and safe in Asian T2DM patients in a real‐world setting, but insulin needs may differ from those in Western countries.